Mechanism of anti-remodelling action of treprostinil in human pulmonary arterial smooth muscle cells.

Mechanism of anti-remodelling action of treprostinil in human pulmonary arterial smooth muscle cells.

Treprostinil is applied for pulmonary arterial hypertension (PAH) therapy. However, the mechanism by which the drug achieves its beneficial effects in PAH vessels is not fully understood. This study investigated the effects of treprostinil on PDGF-BB induced remodelling parameters in isolated human...

Full description

Bibliographic Details
Main Authors:	Christopher Lambers, Christoph Kornauth, Felicitas Oberndorfer, Panja M Boehm, Michael Tamm, Walter Klepetko, Michael Roth
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2018-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC6211661?pdf=render

Similar Items

Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation
by: Christopher Lambers, et al.
Published: (2018-01-01)

Treprostinil Reconstitutes Mitochondrial Organisation and Structure in Idiopathic Pulmonary Fibrosis Cells
by: Lei Fang, et al.
Published: (2023-07-01)

Treprostinil for pulmonary hypertension
by: Nika Skoro-Sajer, et al.
Published: (2008-06-01)

Pulmonary Hypertension-Associated Right Ventricular Cardiomyocyte Remodelling Reduces Treprostinil Function
by: Aleksandra Judina, et al.
Published: (2023-12-01)

IPF-Fibroblast Erk1/2 Activity Is Independent from microRNA Cluster 17-92 but Can Be Inhibited by Treprostinil through DUSP1
by: Sabrina Blumer, et al.
Published: (2021-10-01)

Experiences with treprostinil in the treatment of pulmonary arterial hypertension
by: Amanda R. Stream, et al.
Published: (2012-10-01)

The role of IgE-receptors in IgE-dependent airway smooth muscle cell remodelling.
by: Michael Roth, et al.
Published: (2013-01-01)

The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil
by: Pavel Jansa, et al.
Published: (2023-07-01)

Airway smooth muscle cells respond directly to inhaled environmental factors
by: Michael Roth, et al.
Published: (2010-08-01)

Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
by: Richard W. Chapman, et al.
Published: (2021-02-01)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
by: Carlo Arevalo, et al.
Published: (2022-01-01)

IgE Downregulates PTEN through MicroRNA-21-5p and Stimulates Airway Smooth Muscle Cell Remodeling
by: Lei Fang, et al.
Published: (2019-02-01)

Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension
by: D. Dunbar Ivy, et al.
Published: (2019-07-01)

Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension
by: Susanna Desole, et al.
Published: (2018-12-01)

Smooth muscle tension induces invasive remodeling of the zebrafish intestine.
by: Christoph Seiler, et al.
Published: (2012-01-01)

Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension
by: Adam J. Plaunt, et al.
Published: (2021-01-01)

Role of RASEF hypermethylation in cigarette smoke-induced pulmonary arterial smooth muscle remodeling
by: Qinghai Li, et al.
Published: (2019-03-01)

Airway smooth muscle cells respond directly to inhaled environmental factors
by: Roth M., et al.
Published: (2010-05-01)

Real-world evidence of subcutaneous treprostinil use in pulmonary arterial hypertension in Argentina
by: Adrián Lescano, et al.
Published: (2022-10-01)

Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension
by: Masataka Kuwana, et al.
Published: (2023-01-01)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
by: Nicholas S. Hill, et al.
Published: (2022-07-01)

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
by: Asuka Furukawa, et al.
Published: (2017-10-01)

An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil
by: Marcin Kurzyna, et al.
Published: (2017-12-01)

Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
by: Shireen Mirza, et al.
Published: (2012-07-01)

Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
by: Ifeoma Oriaku, et al.
Published: (2020-03-01)

Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
by: Shireen Mirza, et al.
Published: (2012-01-01)

Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension
by: Pugliese SC, et al.
Published: (2016-01-01)

Treprostinil inhibits functional activation of scleroderma (SSc) vascular smooth muscle cells (vSMCs) by inhibiting Yap and activating PPARG signaling.
by: yongqing wang, et al.
Published: (2023-12-01)

Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience
by: James C. Coons, et al.
Published: (2018-03-01)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
by: Julia McSweeney, et al.
Published: (2023-04-01)

Orotracheal treprostinil administration attenuates bleomycin-induced lung injury, vascular remodeling, and fibrosis in mice
by: Ioanna Nikitopoulou, et al.
Published: (2019-11-01)

Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil
by: John F. Kingrey, et al.
Published: (2023-07-01)

Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension
by: Manuel J. Richter, et al.
Published: (2020-03-01)

Patient Satisfaction with a Dedicated Infusion Pump for Subcutaneous Treprostinil to Treat Pulmonary Arterial Hypertension
by: Marcin Waligóra, et al.
Published: (2023-02-01)

Long-term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics
by: R. James White, et al.
Published: (2020-12-01)

A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension
by: James C. Coons, et al.
Published: (2021-04-01)

Airway Remodeling and Airway Smooth Muscle in Asthma
by: Mitsuru Munakata
Published: (2006-01-01)

Short term effect of intravenous treprostinil in term and preterm infants with pulmonary hypertension
by: Yoo-Jin Kim, et al.
Published: (2024-01-01)

Impact of four times daily dosing of oral treprostinil on tolerability and daily dose achieved in pulmonary hypertension
by: James C. Coons, et al.
Published: (2017-11-01)

DMF inhibits PDGF-BB induced airway smooth muscle cell proliferation through induction of heme-oxygenase-1
by: Tamm Michael, et al.
Published: (2010-10-01)